Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease

· 2014 · New England Journal of Medicine

Abstract

ezumab for this condition. The negative results of these phase 3 trials may be interpreted in two ways: either treatment was too late in the course of the disease or amyloid-beta (Aβ) alone is the wrong target for an effective treatment of Alzheimer’s disease. The first interpretation may be clarified when the results of ongoing treatment trials involving persons with preclinical Alzheimer’s disease are available. These trials include the Dominantly Inherited Alzheimer Network Trial (DIAN-TU; ClinicalTrials.gov number, NCT01760005), Alzheimer’s Prevention Initiative (API; NCT01998841), and the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease study (A4 Study; NCT02008357). The second interpretation has not yet been tested. Several tau-related vaccines are in advanced preclinical stages and will soon enter clinical trials. Since the pathologic process of Alzheimer’s disease is characterized by the accumulation of both amyloid plaques and neurofibrillary tangles, 3 it is reasonable to assume that a treatment strategy focusing on both targets may be more beneficial than a strategy focusing only on one.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc1402193

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 5

  1. 10.1177/1533317513494457 · DOI
  2. 10.1056/NEJMoa1312889 · DOI · Paper page
  3. 10.1056/NEJMe1313943 · DOI · Paper page
  4. 10.1056/NEJMoa1304839 · DOI · Paper page
  5. 10.1056/NEJMoa1312889 · DOI · Paper page

Cited by

See all 169

Metadata

Venue
New England Journal of Medicine
Published
2014-04-10
Volume
370
Issue
15
Pages
1459-1460
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1268992491
Cited by
169
References
5
FWCI
13.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease. https://app.cochat.ai/papers/10.1056/nejmc1402193
The paper
Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease. (2014). New England Journal of Medicine. https://doi.org/10.1056/nejmc1402193

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.